Surgery: light – thermal – and electrical application – Light – thermal – and electrical application – Thermal applicators
Reexamination Certificate
2000-04-20
2002-12-03
Cohen, Lee (Department: 3739)
Surgery: light, thermal, and electrical application
Light, thermal, and electrical application
Thermal applicators
C607S096000, C607S100000, C607S101000, C607S104000, C607S105000
Reexamination Certificate
active
06490488
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention relates to a method for treating tissue. In particular, the present invention relates to a method of controlling thermal therapy of tissue such as the prostate to enhance treatment effectiveness with minimal treatment time.
The prostate gland is a complex, chestnut-shaped organ which encircles the urethra immediately below the bladder. Nearly one third of the prostate tissue anterior to the urethra consists of fibromuscular tissue that is anatomically and functionally related to the urethra and the bladder. The remaining two thirds of the prostate is generally posterior to the urethra and is comprised of glandular tissue. The portion of the urethra extending through the prostate (i.e., the prostatic urethra) includes a proximal segment, which communicates with the bladder, and a distal segment, which extends at an angle relative to the proximal segment by the verumontanum.
Although a relatively small organ, the prostate is the most frequently diseased of all internal organs and is often the site of a common affliction among older men, benign prostatic hyperplasia (BPH), as well as a more serious affliction, cancer. BPH is a nonmalignant, bilateral expansion of prostate tissue occurring mainly in the transition zone of the prostate adjacent to the proximal segment of the prostatic urethra. As this tissue grows in volume, it encroaches on the urethra extending into the region of the bladder neck at the base of the bladder. Left untreated, BPH causes obstruction of the urethra which usually results in increased urinary frequency, urgency, incontinence, nocturia and slow or interrupted urinary stream. BPH may also result in more severe complications, such as urinary tract infection, acute urinary retention, hydronephrosis and uraemia.
Benign prostatic hyperplasia (BPH) may be treated using transurethral thermal therapy as described in further detail in U.S. Pat. No. 5,620,480 entitled METHOD FOR TREATING BENIGN PROSTATIC HYPERPLASIA WITH THERMAL THERAPY and in U.S. Pat. No. 5,575,811 entitled BENIGN PROSTATIC HYPERPLASIA TREATMENT CATHETER WITH URETHRAL COOLING, both of which are hereby incorporated by reference. During transurethral thermal therapy, the transition zone of the prostate is heated to necrose the tumorous tissue that encroaches on the urethra. Transurethral thermal therapy is administered by use of a microwave antenna-containing catheter which includes a multi-lumen shaft. The catheter is positioned in the urethra with the microwave antenna located adjacent to the hyperplastic prostatic tissue. Energization of the microwave antenna causes the antenna to emit electromagnetic energy which heats tissue within the prostate. A cooling fluid is circulated through the catheter to preserve tissue such as the urethral wall between the microwave antenna and the target tissue of the prostate.
The primary goal of transurethral thermal therapy is to necrose prostate tissue while preserving adjacent healthy tissue. It is also preferable to achieve this goal in as short of a time as is possible, consistent with the patient's level of tolerance and comfort. In addition, it is important that the rectum be preserved from unduly high temperatures, since it is susceptible to thermal damage. There is an ongoing need in the art for a method of controlling thermal therapy that reduces treatment time and enhances effectiveness consistent with all of these parameters.
SUMMARY OF THE INVENTION
The present invention is a method of treating tissue with heat from an adjacent body cavity, such as treating a prostate with heat delivered from a urethra. An applicator including an energy-emitting device is inserted into the body cavity adjacent the targeted tissue region. The energy-emitting device is energized, thereby delivering energy to the targeted tissue region, and coolant is circulated between the energy-emitting device and a wall of the body cavity. A temperature of the coolant circulated is continually controlled based on therapy parameters. For example, where the targeted tissue region is the prostate adjacent the urethra, rectal temperature is monitored and, upon sensing a rectal temperature that exceeds a predetermined threshold, coolant temperature is increased. Patient comfort indicators are also an example of therapy parameters upon which continuous control of the coolant temperature may be based. The applicator, or selected tissue at a predetermined depth from the wall of the body cavity, is maintained at a temperature corresponding to a predetermined applicator temperature profile by adjusting a power level provided to the energy-emitting device.
REFERENCES:
patent: 4190053 (1980-02-01), Sterzer
patent: 4375220 (1983-03-01), Matvias
patent: 4601296 (1986-07-01), Yerushalmi
patent: 4662383 (1987-05-01), Sogawa et al.
patent: 4676258 (1987-06-01), Inokuchi et al.
patent: 4813429 (1989-03-01), Eshel et al.
patent: 4967765 (1990-11-01), Turner et al.
patent: 5007437 (1991-04-01), Sterzer
patent: 5097829 (1992-03-01), Quisenberry
patent: 5231997 (1993-08-01), Kikuchi et al.
patent: 5234004 (1993-08-01), Hascoet et al.
patent: 5304214 (1994-04-01), DeFord et al.
patent: 5330518 (1994-07-01), Neilson et al.
patent: 5344435 (1994-09-01), Turner et al.
patent: 5391197 (1995-02-01), Burdette et al.
patent: 5404881 (1995-04-01), Cathaud et al.
patent: 5413588 (1995-05-01), Rudie et al.
patent: 5423811 (1995-06-01), Imran et al.
patent: 5433740 (1995-07-01), Yamaguchi
patent: 5464437 (1995-11-01), Reid et al.
patent: 5464445 (1995-11-01), Rudie et al.
patent: 5480417 (1996-01-01), Hascoet et al.
patent: 5496271 (1996-03-01), Burton et al.
patent: 5509929 (1996-04-01), Hascoet et al.
patent: 5520684 (1996-05-01), Imran
patent: 5545137 (1996-08-01), Rudie et al.
patent: 5575811 (1996-11-01), Reid et al.
patent: 5620480 (1997-04-01), Rudie
patent: 5624382 (1997-04-01), Oppelt et al.
patent: 5628770 (1997-05-01), Thome et al.
patent: 5643335 (1997-07-01), Reid et al.
patent: 5676692 (1997-10-01), Sanghvi et al.
patent: 5733319 (1998-03-01), Neilson et al.
patent: 5755754 (1998-05-01), Rudie et al.
patent: 5759162 (1998-06-01), Oppelt et al.
patent: 5792070 (1998-08-01), Kauphusman et al.
patent: 5800486 (1998-09-01), Thome et al.
patent: 5807395 (1998-09-01), Mulier et al.
patent: 5843144 (1998-12-01), Rudie et al.
patent: 5861021 (1999-01-01), Rudie et al.
patent: 5899932 (1999-05-01), Dann et al.
patent: 5916240 (1999-06-01), Rudie et al.
patent: 5916241 (1999-06-01), Rudie et al.
patent: 5931860 (1999-08-01), Reid et al.
patent: 5938692 (1999-08-01), Rudie
patent: 5951546 (1999-09-01), Lorentzen
patent: 5987360 (1999-11-01), McGrath et al.
patent: 6007571 (1999-12-01), Neilson et al.
patent: 6051018 (2000-04-01), Larsen
patent: 6122551 (2000-09-01), Rudie et al.
patent: 6216041 (2001-04-01), Tierney et al.
patent: 6302878 (2001-10-01), Daikuzono
patent: WO 94/02204 (1994-02-01), None
Burgett James E.
Flachman Jonathan L.
Larson Thayne R.
Rudie Eric N.
Cohen Lee
Johnson Henry M.
Kinney & Lange , P.A.
Urologix Inc.
LandOfFree
Method of controlling thermal therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of controlling thermal therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of controlling thermal therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2920292